南美超级胎牛血清999尝鲜特惠
转染试剂低至5折
基质胶阶梯特惠
积分商城,好礼送不停
南美超级胎牛血清999尝鲜特惠
转染试剂低至5折
基质胶阶梯特惠
积分商城,好礼送不停
分子生物学
IVD分子诊断
细胞培养与分析
蛋白研究
细胞因子
重组蛋白
抗体
高通量测序建库
病原检测UCF系列
生物医药
工具酶
抑制剂激活剂与常用试剂
仪器
耗材

载有SRT1720的拟外泌体纳米微泡,通过激活SIRT1/PARKIN蛋白促进线粒体自噬,有效缓解糖尿病性脑梗死症状——这一研究成果已在临床前大鼠模型中得到验证。

SRT1720-loaded exosome-mimetic nanovesicles promote mitophagy via SIRT1/PARKIN activation to ameliorate diabetic cerebral infarction in a preclinical rat model

Qifeng Huang, Fang Zhao, Bo Sun, Xie Yang, Miao Chen

Journal:International Journal of Pharmaceutics-X

IF:7.9

DOI:10.1016/j.ijpx.2026.100639

PMID:

Published:2026-08-13

research field:神经科学线粒体生物学糖尿病研究脑血管疾病分子药理学纳米医学

Abstract

Mitochondrial dysfunction and impaired mitophagy-a key event in diabetic hyperglycemia-aggravated ischemic injury - lead to accumulation of dysfunctional mitochondria and neuronal apoptosis, which are vital processes involved in diabetic cerebral infarction (DCI). Herein, we developed SRT1720-loaded exosome-mimetic nanovesicles (SRT1720@M) to leverage the potential of SIRT1/PARKIN pathway activation to inhibit these processes and counteract DCI. The lipid fusion approach was used to fabricate exosome-loaded SRT1720@M. The properties of SRT1720@M were established by employing UV–Vis, transmission electron microscopy (TEM), dynamic light scattering, and Fourier-transform infrared (FTIR) spectroscopy. Oxygen-glucose deprivation/reperfusion (OGD/R) and high-glucose (HG)-treated primary hippocampal neurons were used as an in vitro DCI model treated with SRT1720@M. qPCR, Western blotting and immunofluorescence were used for expression analyses, whereas cell viability, phagocytosis, inflammation, and ATP/L-LA levels were assessed by CCK-8, ELISA and TEM. A rat model of DCI was obtained by establishing middle cerebral artery occlusion (MCAO), from which infarct volume, neurological deficits, histopathology, behavioral indexes, and molecular markers were detected. SRT1720@M average size was ~68 nm, with an encapsulation efficiency of 78.19%, loading capacity of 8.52%, and zeta potential of −54 mV. In vitro, SRT1720@M markedly improved cell viability ( P  < 0.01), decreased IL-1β, TNF-α, and L-LA, but increased ATP levels, and promoted mitophagy and suppressed inflammatory responses compared with the DCI group. In the DCI model, SRT1720@M improved neurological deficits, reduced infarct volume, and alleviated behavioral disorders by inhibiting apoptosis and inflammation and promoting mitophagy and mitochondrial function through activation of the SIRT1/PARKIN pathway. SRT1720@M alleviates DCI by activating the SIRT1/PARKIN pathway and promoting mitophagy, highlighting its pote

本文使用的Yeasen产品

购物车
客服
转染试用